GF Fund Management
AVBP icon

GF Fund Management’s ArriVent BioPharma AVBP Stock Holding History

GF Fund Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$37.9K Buy
1,252
+375
+43% +$11.5K ﹤0.01% 428
2026
Q2 		$30.5K Sell
877
-42
-5% -$1.24K ﹤0.01% 444
2026
Q1 		$21.2K Buy
919
+108
+13% +$2.44K ﹤0.01% 497
2025
Q4 		$16.3K Sell
811
-62
-7% -$1.29K ﹤0.01% 528
2025
Q3 		$16.1K Buy
873
+10
+1% +$196 ﹤0.01% 516
2025
Q2 		$18.8K Hold
863
– – ﹤0.01% 508
2025
Q1 		$16K Buy
863
+155
+22% +$3.79K ﹤0.01% 522
2024
Q4 		$18.9K Buy
+708
New +$20.3K ﹤0.01% 477

Other funds holding AVBP

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return

GF Fund Management's AVBP Position: Q3 2026 in Review

GF Fund Management increased its ArriVent BioPharma (AVBP) stake by 43% in Q3 2026, buying an estimated $11.5K and bringing the position to 1,252 shares worth $37.9K. The position accounts for ﹤0.01% of the portfolio, ranked #428.

GF Fund Management first reported a position in AVBP in Q4 2024 and has held it in 8 quarters since. 18 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • GF Fund Management held 1,252 shares of ArriVent BioPharma worth $37.9K as of Q3 2026.
  • GF Fund Management bought 375 ArriVent BioPharma shares in Q3 2026, an estimated $11.5K.
  • ArriVent BioPharma made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #428 holding.
  • GF Fund Management first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 8 quarters since.
  • 18 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.